scholarly journals Characterization of the Serum Levels of Meteorin-like in Patients with Inflammatory Bowel Disease and its Association with Inflammatory Cytokines 

2020 ◽  
Author(s):  
Afsane Gholamrezayi ◽  
Maryam Mohamadinarab ◽  
Pegah Rahbarinejad ◽  
Soudabeh Fallah ◽  
Shekufe Rezghi Barez ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Serum Levels ◽  
Pathological Examination ◽  
Tnf Α ◽  
Healthy Control ◽  
Patient Groups ◽  
Inflammatory Bowel ◽  
Necrosis Factor

Abstract Background: Meteorin-like (Metrnl) is an adipokine with insulin sensitizing and anti-inflammatory properties that has been discovered recently. The relation among Metrnl, Inflammatory Bowel Disease (IBD), and obesity has been unexplored yet. Methods: The present study was conducted on 54 healthy control, 42 Ulcerative Colitis (UC), and 43 Crohn's disease (CD) patients who were diagnosed by pathological examination. In all participants, serum levels of adiponectin, Metrnl, interleukin (IL)-6, and Tumor necrosis factor (TNF-α) were measured using ELISA kits.Results: Metrnl concentration was considerably lower in both UC (85.25±36.55 pg/mL) and CD (76.93±27.92 pg/mL) patients in comparison to control (107.52 ± 35.33 pg/mL). In addition, it was seen that both patient groups have a decreased level of adiponectin compared to the controls. Besides that, the level of IL-6 and TNF-α were significantly greater in the patient groups. Moreover, the result showed that the level of Metrnl is inversely correlated with body mass index (BMI) in the controls and the patients. Metrnl levels are also inversely associated with IL-6, and TNF-α in both of the patient groups.Conclusions: The current study is the first one reporting the decreased levels of Metrnl in serum among patients with IBD, which is inversely related with BMI, TNF-α, and IL-6. These results suggested a possible relation of Metrnl with the pathogenesis of IBD, particularly through inflammatory process, although further studies are warranted to dissect the possible mechanism.

scholarly journals Characterization of the Serum Levels of Meteorin-like in Patients with Inflammatory Bowel Disease and its Association with Inflammatory Cytokines

2020 ◽  
Author(s):  
Afsane Gholamrezayi ◽  
Maryam Mohamadinarab ◽  
Pegah Rahbarinejad ◽  
Soudabeh Fallah ◽  
Shekufe Rezghi Barez ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Serum Levels ◽  
Pathological Examination ◽  
Tnf Α ◽  
Healthy Control ◽  
Patient Groups ◽  
Inflammatory Bowel ◽  
Necrosis Factor

Abstract Background: Meteorin-like (Metrnl) is an adipokine with insulin sensitizing and anti-inflammatory properties that has been discovered recently. The relation among Metrnl, Inflammatory Bowel Disease (IBD), and obesity has been unexplored yet. Methods: The present study was conducted on 54 healthy control, 42 Ulcerative Colitis (UC), and 43 Crohn's disease (CD) patients who were diagnosed by pathological examination. In all participants, serum levels of adiponectin, Metrnl, interleukin (IL)-6, and Tumor necrosis factor (TNF-α) were measured using ELISA kits.Results: Metrnl concentration was considerably lower in both UC (85.25±36.55 pg/mL) and CD (76.93±27.92 pg/mL) patients in comparison to control (107.52 ± 35.33 pg/mL). In addition, it was seen that both patient groups have a decreased level of adiponectin compared to the controls. Besides that, the level of IL-6 and TNF-α were significantly greater in the patient groups. Moreover, the result showed that the level of Metrnl is inversely correlated with body mass index (BMI) in the controls and the patients. Metrnl levels are also inversely associated with IL-6, and TNF-α in both of the patient groups.Conclusions: The current study is the first one reporting the decreased levels of Metrnl in serum among patients with IBD, which is inversely related with BMI, TNF-α, and IL-6. These results suggested a possible relation of Metrnl with the pathogenesis of IBD, particularly through inflammatory process, although further studies are warranted to dissect the possible mechanism.

scholarly journals Characterization of the serum levels of Meteorin-like in patients with inflammatory bowel disease and its association with inflammatory cytokines

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Afsane Gholamrezayi ◽  
Maryam Mohamadinarab ◽  
Pegah Rahbarinejad ◽  
Soudabeh Fallah ◽  
Shekufe Rezghi Barez ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Serum Levels ◽  
Pathological Examination ◽  
Tnf Α ◽  
Healthy Control ◽  
Patient Groups ◽  
Inflammatory Bowel ◽  
Necrosis Factor

Abstract Background Meteorin-like (Metrnl) is an adipokine with insulin sensitizing and anti-inflammatory properties that has been discovered recently. The relation among Metrnl, Inflammatory Bowel Disease (IBD), and obesity has been unexplored yet. Methods The present study was conducted on 54 healthy control, 42 Ulcerative Colitis (UC), and 43 Crohn’s disease (CD) patients who were diagnosed by pathological examination. In all participants, serum levels of adiponectin, Metrnl, interleukin (IL)-6, and Tumor necrosis factor (TNF-α) were measured using ELISA kits. Results Metrnl concentration was considerably lower in both UC (85.25 ± 36.55 pg/mL) and CD (76.93 ± 27.92 pg/mL) patients in comparison to control (107.52 ± 35.33 pg/mL). In addition, it was seen that both patient groups have a decreased level of adiponectin compared to the controls. Besides that, the level of IL-6 and TNF-α were significantly greater in the patient groups. Moreover, the result showed that the level of Metrnl is inversely correlated with body mass index (BMI) in the controls and the patients. Metrnl levels are also inversely associated with IL-6, and TNF-α in both of the patient groups. Conclusions The current study is the first one reporting the decreased levels of Metrnl in serum among patients with IBD, which is inversely related with BMI, TNF-α, and IL-6. These results suggested a possible relation of Metrnl with the pathogenesis of IBD, particularly through inflammatory process, although further studies are warranted to dissect the possible mechanism.

scholarly journals Characterization of the Metrnl Serum Levels in Patients with Inflammatory Bowel Disease and its Association with Inflammatory Cytokines

2020 ◽  
Author(s):  
Afsane Gholamrezayi ◽  
Maryam Mohamadinarab ◽  
Pegah Rahbarinejad ◽  
Soudabeh Fallah ◽  
Shekufe Rezghi Barez ◽  
...  
Keyword(s):  
Inverse Correlation ◽  
Serum Levels ◽  
Pathological Examination ◽  
Control Group ◽  
Body Tissues ◽  
Tnf Α ◽  
Healthy Control ◽  
Patient Groups ◽  
Inflammatory Bowel

Abstract Background Meteorin-like (Metrnl) is a newly discovered adipokine with the anti-inflammatory and insulin sensitizing properties. Accordingly, Metrnl regulates glucose tolerance, enhances metabolism in body tissues, and induces thermogenesis in white adipose tissue. However, the correlation among Metrnl, IBD, and obesity still remains unexplored. Methods The present study was conducted on 54 healthy control, 42 Ulcerative Colitis (UC), and 43 Crohn's disease (CD) patients who were diagnosed by pathological examination. In these patients, serum levels of adiponectin, Metrnl, IL-6, and TNF-α were measured using ELISA kits. Results Metrnl concentration significantly decreased in both of the UC (85.25 ± 36.55 pg/mL) and CD (76.93 ± 27.92 pg/mL) patients compared to control group (107.52 ± 35.33 pg/mL). Similarly, adiponectin has also decreased in these two patient groups compared to the controls. However, IL-6 and TNF-α significantly increased in both of the patient groups. Moreover, Metrnl indicated an inverse relationship with BMI in the controls and both of the patient groups. In addition, there was an inverse correlation among Metrnl, IL-6, and TNF-α in both of the patient groups. Conclusions The current study is the first one reporting the decreased Metrnl serum level in the patients with IBD, which is inversely related to BMI, TNF-α, and IL-6. These results suggested a possible role for Metrnl in the pathogenesis of IBD, particularly through inflammation modulating.

scholarly journals Characterization of the Serum Levels of Meteorin-like in Patients with Inflammatory Bowel Disease and its Association with Inflammatory Cytokines

2020 ◽  
Author(s):  
Afsane Gholamrezayi ◽  
Maryam Mohamadinarab ◽  
Pegah Rahbarinejad ◽  
Soudabeh Fallah ◽  
Shekufe Rezghi Barez ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Tumor Necrosis ◽  
Inverse Correlation ◽  
Serum Levels ◽  
Tnf Α ◽  
Patient Groups ◽  
Inflammatory Bowel ◽  
Necrosis Factor

Abstract Background : Meteorin-like (Metrnl) is a newly discovered adipokine with insulin sensitizing and anti-inflammatory properties. The relation among Metrnl, Inflammatory Bowel Disease (IBD), and obesity still remained unexplored. Methods : The present study was conducted on 54 healthy control, 42 Ulcerative Colitis (UC), and 43 Crohn's disease (CD) patients who were diagnosed by pathological examination. In all participants, serum levels of adiponectin, Metrnl, interleukin (IL)-6, and Tumor necrosis factor (TNF-α) were measured using ELISA kits.Results: Metrnl concentration was considerably decreased in both UC (85.25±36.55 pg/mL) and CD (76.93±27.92 pg/mL) patients in comparison to control group (107.52±35.33 pg/mL). In addition, the level of adiponectin decreased in these two patient groups compared to the controls. However, IL-6 and TNF-α significantly elevated in the patient groups. Moreover, Metrnl showed an inverse correlation with body mass index (BMI) in the controls and the patients. In addition, there was an inverse correlation among Metrnl, IL-6, and TNF-α in both of the patient groups. Conclusions : The current study is the first one reporting the decreased serum levels of Metrnl in patients with IBD, which is inversely related with BMI, TNF-α, and IL-6. These results suggested a possible relation of Metrnl with the pathogenesis of IBD, particularly through inflammatory process that need further study to dissect the possible mechanism. Keywords : Meteorin-like, Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's disease, Interleukin, Tumor necrosis factor, Adiponectin

scholarly journals P415 Paradoxical onset of Takayasu’s arteritis in patients with inflammatory bowel disease treated with anti-tumour necrosis factor-α agents

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S422-S422
Author(s):  
Y Matsune ◽  
J Kouyama ◽  
Y Tsuru ◽  
K Shimizu ◽  
S Asami ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Features ◽  
Bowel Disease ◽  
Tumour Necrosis ◽  
Rare Complication ◽  
Tumour Necrosis Factor Α ◽  
Tnf Α ◽  
Inflammatory Bowel ◽  
Factor Α ◽  
Necrosis Factor

Abstract Background Takayasu’s arteritis (TA) is a rare complication associated with inflammatory bowel disease (IBD). TA is a granulomatous systemic vasculitis of uncertain aetiology affecting large arteries, predominantly the aorta and its main branches, leading to stenotic and expansible lesions. The estimated prevalence of coexisting of TA in patients with ulcerative colitis (UC) is 0.3%, and that in patients with Crohn’s disease (CD) is 0.1%. Anti-tumour necrosis factor-α (TNF-α) agents are used to treat both TA and IBD, although some patients with IBD paradoxically develop TA during treatment with anti-TNF-α agents. However, data regarding the incidence and clinical features of TA in such cases are lacking. This study was performed to clarify the prevalence, risk factors, and clinical features of TA that develops paradoxically during treatment with anti-TNF-α agents in patients with IBD. Methods Consecutive patients with IBD who were regularly seen at our centre, a tertiary IBD centre in Japan, from 2000 to 2019 were included in this retrospective single-centre study. We evaluated the prevalence of TA according to the presence or absence of treatment with anti-TNF-α agents and the patients’ clinical manifestations. Results Of 1846 patients with UC and 1249 patients with CD, 7 (0.23%) patients with UC developed TA. The prevalence of TA in patients treated with anti-TNF-α agents was significantly higher (4/254, 1.6%) than that in patients without anti-TNF-α agent treatment (3/1592, 0.19%) (p=0.0087, Fisher’s exact test). Among four patients with UC who paradoxically developed TA during treatment with anti-TNF-α agents, three (75%) received infliximab, one (25%) received adalimumab, and one (25%) received golimumab. One was male and three (75%) were female. The median interval from starting treatment with anti-TNF-α agents to diagnosis of TA was 49.0 (34–63) months. All patients had pancolitis as well as persistent active colitis resistant to anti-TNF-α antibody treatment. The treatments for TA administered after anti-TNF-α therapy were as follows: Two (50%) patients discontinued anti-TNF-α agent therapy, three (75%) were treated with prednisolone, and one (25%) received tocilizumab. No patient required an operation for TA. Conclusion To our knowledge, this is the first study to show the prevalence and clinical features of TA in patients with IBD following administration of anti-TNF-α agent therapy. Although TA is a rare complication, our results suggest that it can develop as paradoxical reaction following administration of anti-TNF-α agents.

scholarly journals Joint lesions in inflammatory bowel diseases: the analysis of the Moscow regional patient registry and a clinical case

2020 ◽  
Vol 48 (6) ◽  
pp. 395-402
Author(s):  
O. V. Taratina ◽  
E. A. Belousova
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Case ◽  
Moscow Region ◽  
Tnf Α ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
The Mean ◽  
The Given ◽  
Necrosis Factor

Rationale: Extraintestinal manifestations (EIM) of an inflammatory bowel disease (IBD) are a sign of its more severe course. Joint lesions are most common among IBD EIM.Aim: To evaluate the prevalence and types of joint lesions in the population of IBD patients of the Moscow region.Materials and methods: We performed a  retrospective analysis of medical files of the patients who were admitted to the Moscow Region Inflammatory Bowel Disease Center (MONIKI) for examination and treatment from August 1, 2019, to March 1, 2020. The study included 70 patients with confirmed diagnoses of IBD and confirmed or suspected involvement of the joints.Results: Thirty six of 70 patients with IBD and EIM (51.43%) had been diagnosed with Crohn's disease (CD), and 34 (48.57%) with ulcerative colitis (UC). The CD group included more men (n=21, 58.33%), whereas their proportion in the UC group was 47.02% (n=16). The mean age at CD diagnosis in the UC and CD groups was comparable: 38.3±13.7  years in men with CD and 40.5±12.8 years in men with UC, 37.7±11.1 years in women with CD and 35.7±14.0 in women with UC. The most prevalent among all IBD patients were X-ray negative peripheral arthralgias. Among joint lesions confirmed by radiological diagnostics, sacroileitis was most prevalent both in all IBD patients (24.3%), as well as in the UC group (17.6%), whereas in the CD patients its frequency was the same as that of ankylosing spondyloarthritis (AS) (30.6% of the cases). AS ranked second in the prevalence of joint lesions in the UC group (8.8%) and all IBD (20%). Psoriatic arthritis was diagnosed only in the CD patients (2 / 36). We describe a clinical case of CD with AS, complicated with psoriatic rash, treated with a  monoclonal antibody to tumor necrosis factor alfa (anti-TNF-α).Conclusion: Peripheral arthropathias were most prevalent among all joint lesions in the group studied. EIM mirror a more aggressive phenotype of the disease and higher glucocorticosteroids requirements. Administration of anti-TNF-α agents allows for the control of both intestinal IBD manifestations and of the joint syndrome. However, drug-associated skin adverse event can occur during treatment with this drug class. In such a case, it is possible to switch the biological therapy to another class of drugs that we have demonstrated with the given clinical example.

Monitoring of serum levels of infliximab and anti-infliximab antibodies and its role in optimizing therapy of inflammatory bowel disease in children

2021 ◽  
Vol 16 (2) ◽  
pp. 14-21
Author(s):  
A.S. Illarionov ◽  
◽  
S.V. Petrichuk ◽  
A.P. Fisenko ◽  
T.V. Radygina ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Treatment Efficacy ◽  
Clinical Remission ◽  
Serum Levels ◽  
Enzyme Linked Immunosorbent Assay ◽  
Residual Level ◽  
Inflammatory Bowel ◽  
Factor Α ◽  
Necrosis Factor

Objective. To evaluate the prognostic value of serum levels of infliximab (IFX) and anti-IFX antibodies for predicting treatment efficacy in children with inflammatory bowel disease (IBD). Patients and methods. This study included 123 children with IBD (65 patients with ulcerative colitis (UC) and 58 patients with Crohn's disease (CD)) aged between 3 and 18 years. Children were examined upon the completion of an induction course of therapy and then after 1 year of therapy and between 1 and 3 years of treatment. The induction course was administered according to the scheme of 0–2–6 weeks; maintenance therapy was administered with 6-week and 8-week intervals. The residual level of IFX and the level of anti-IFX antibodies in serum were measured using enzyme-linked immunosorbent assay. Results. We observed a significant increase in the IFX level during clinical remission of CD (remission – 5.21 [3.32; 7.43] μg/mL; exacerbation – 2.42 [0.42; 4.51] μg/mL, p = 0.001) and UC (remission – 4.57 [3.4; 6.74] μg/mL; exacerbation – 0.63 [0.4; 3.27] μg/mL, p = 0.000). ROC analysis demonstrated high accuracy of our model based on measuring residual IFX level for distinguishing between exacerbation and remission in both CD patients (AUC = 0.812) and UC patients (AUC = 0.851). The optimal minimum level of IFX for maintaining clinical remission was 3.7 μg/mL in children with CD and 3.4 μg/mL in children with UC. Anti-IFX antibodies were detected in 18% of patients; children with exacerbation were 4.7 times more likely to have detectable level of anti-IFX antibodies than those in clinical remission. Conclusion. Monitoring of serum levels of IFX and anti-IFX antibodies is a promising method for predicting treatment efficacy and its optimization in children with IBD. Key words: inflammatory bowel disease, tumor necrosis factor-α, infliximab, residual level of infliximab, anti-infliximab antibodies

Antitumor Necrosis Factor-α Therapy Associated with Inflammatory Bowel Disease: Three Cases and a Systematic Literature Review

2017 ◽  
Vol 44 (7) ◽  
pp. 1088-1095 ◽  
Author(s):  
Amir Bieber ◽  
Abdallah Fawaz ◽  
Irina Novofastovski ◽  
Reuven Mader
Keyword(s):  
Inflammatory Bowel Disease ◽  
Literature Review ◽  
Bowel Disease ◽  
Gastrointestinal Symptoms ◽  
Case Series ◽  
Patient Specific ◽  
Tnf Α ◽  
Inflammatory Bowel ◽  
Factor Α ◽  
Necrosis Factor

Objective.Antitumor necrosis factor-α (anti-TNF-α) therapy is the most prescribed biologic agent therapy in rheumatology and gastroenterology. However, a number of serious side effects have been reported with these drugs. Only a handful of cases of new-onset inflammatory bowel disease (IBD), mostly in children diagnosed with juvenile idiopathic arthritis (JIA), have been reported during anti-TNF-α therapy. We present 3 cases of adult IBD following anti-TNF-α therapy and a literature review on this topic.Methods.We searched PubMed MESH for all relevant terms, papers were reviewed, and patient-specific data were extracted. Relevant clinical data were calculated and presented.Results.The PubMed search resulted in 137 articles, of which 11 articles and 4 cited publications were included in our analysis. We found 53 cases of IBD after anti-TNF-α therapy reported in the literature; most of them were case series collected retrospectively from national databases or studies. Almost all the patients developed IBD after the introduction of etanercept (ETN); 2 patients with rheumatoid arthritis were also included. The average age at IBD onset was 17.3 years and the average time from ETN introduction to IBD onset was 27 months (± 24). Gastrointestinal symptoms have been reported as improving or subsiding in most of the patients after discontinuing ETN.Conclusion.Although this manifestation is not common, it should be taken into consideration as an adverse effect of ETN. Rheumatologists, and in particular rheumatologists treating adult patients, should be aware of this possible complication. Further investigation about the pathogenic process underlying this phenomenon is warranted.

Mo1202 Characterization of Anti-Tumor Necrosis Factor Agent-Induced Lupus in Patients With Inflammatory Bowel Disease

2014 ◽  
Vol 146 (5) ◽  
pp. S-585
Author(s):  
Travis B. Murdoch ◽  
Laura Stinton ◽  
Remo Panaccione ◽  
Gilaad Kaplan ◽  
Subrata Ghosh ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Tumor Necrosis Factor ◽  
Bowel Disease ◽  
Tumor Necrosis ◽  
Inflammatory Bowel ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document